Common molecular aberrations included CEBPA bZip mutations (40%) and CBF fusions (23%), as well as secondary‐type AML‐associated mutations such as those in ASXL1, SRSF2, and EZH2. The gene discussed is SRSF2; the disease is acute myeloid leukemia.